<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732392</url>
  </required_header>
  <id_info>
    <org_study_id>2012-07</org_study_id>
    <secondary_id>2012-A-000287-36</secondary_id>
    <nct_id>NCT02732392</nct_id>
  </id_info>
  <brief_title>Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer</brief_title>
  <acronym>SENTINELLE</acronym>
  <official_title>Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of a ganglionic infringement(achievement) at a patient reached (affected) by a&#xD;
      prostate cancer is a factor(mailman) of bad forecast. The locoregional ganglionic staging is&#xD;
      a very important element in the coverage (care). He allows to determine the local extension&#xD;
      of the disease and the type(chap) of therapeutics to implement(operate) after the surgery.&#xD;
      The standard cleaning out at present recommended by the European company (society) of urology&#xD;
      at the patients at intermediate or high risk of second offense (recurrence) after local&#xD;
      treatment(processing), has to concern the obturating pit, the internal and external iliac&#xD;
      territories. However this type(chap) of cleaning out does not seem to solve all the problems&#xD;
      of locoregional stratification. Indeed, several studies concerning the radio-controlled&#xD;
      cleaning out highlighted that 10 in 30% of ganglions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of sentinel nodes radiolabeled</measure>
    <time_frame>54 months</time_frame>
    <description>Number of sentinel nodes radiolabeled radiolabeled in the area of standard cleaning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of sentinel nodes radiolabeled</measure>
    <time_frame>54 months</time_frame>
    <description>Number of sentinel nodes radiolabeled outside the standard cleaning of territory</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Patient With Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard lymphadenectomy</intervention_name>
    <arm_group_label>lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphadenectomy radio-isotope method</intervention_name>
    <arm_group_label>lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject man, whose age is greater than or equal to 18 years&#xD;
&#xD;
          -  Carrier of cancer intermediate risk non-metastatic prostate or high relapse&#xD;
&#xD;
          -  Subject with an initial balance sheet expansion, regional and general negative by&#xD;
             Scanner, abdominopelvic MRI or bone scan,&#xD;
&#xD;
          -  Subject has undergone a medical examination in connection with the study,&#xD;
&#xD;
          -  Topic for which a radical prostatectomy is considered curative purposes,&#xD;
&#xD;
          -  Supported by Subject surgical teams involved in the study,&#xD;
&#xD;
          -  Topic affiliated to a social security scheme,&#xD;
&#xD;
          -  Subject who signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject man, whose age is less than 18 years&#xD;
&#xD;
          -  Subject who have received hormone therapy or radiation therapy for prostate cancer&#xD;
&#xD;
          -  Subject who had surgery for prostate adenoma (transurethral resection or open surgery)&#xD;
             because of potential difficulties injection of radioactive tracer in the gland,&#xD;
&#xD;
          -  Subject has a history of pelvic surgery or radiotherapy,&#xD;
&#xD;
          -  Subject with inguinal hernia repair history of laparoscopic,&#xD;
&#xD;
          -  Subject refusing blood transfusions,&#xD;
&#xD;
          -  Subject is not agreeing to participate in this study and did not sign the informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cyrille BASTIDE, PUPH</last_name>
    <phone>04.91.96.87.18</phone>
    <email>cyrille.bastide@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique HÃ´pitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urielle DESALBRES, Director</last_name>
      <phone>04.91.38.27.47</phone>
      <email>drci@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

